Discounted Cash Flow (DCF) Analysis Unlevered

Orphazyme A/S (ORPH)

$ 23.0201
12.9701 (+129.06%)

Operating Data

Year
A/P
2015
Projected
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -----------
Revenue (%)
EBITDA -----------
EBITDA (%)
EBIT -----------
EBIT (%)
Depreciation -----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash -----------
Total Cash (%)
Account Receivables -----------
Account Receivables (%)
Inventories -----------
Inventories (%)
Accounts Payable -----------
Accounts Payable (%)
Capital Expenditure -----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 23.0,201
Beta 0.813
Diluted Shares Outstanding 20
Cost of Debt
Tax Rate 0.30
After-tax Cost of Debt 4.98%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.934
Total Debt 57.18
Total Equity 460.45
Total Capital 517.63
Debt Weighting 11.05
Equity Weighting 88.95
Wacc

Build Up Free Cash

Year
A/P
2015
Projected
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -----------
EBITDA -----------
EBIT -----------
Tax Rate 10.65%8.67%4.18%2.34%1.60%0.30%4.62%4.62%4.62%4.62%4.62%
EBIAT -----------
Depreciation -----------
Accounts Receivable -----------
Inventories -----------
Accounts Payable -----------
Capital Expenditure -0.49-0.24-1.49-2.35-3.29-5.10-----
UFCF -----------
WACC
PV UFCF -----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 8.50
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -669.75
Equity Value -
Shares Outstanding 20
Equity Value Per Share -